NLVP
VTGN icon

New Leaf Venture Partners’s VistaGen Therapeutics VTGN Stock Holding History

New Leaf Venture Partners’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-11,765
Closed -$1.32M – 19
2016
Q4 		$1.32M Hold
11,765
– – 0.94% 11
2016
Q3 		$1.49M Hold
11,765
– – 1.07% 11
2016
Q2 		$1.38M Buy
+11,765
New +$1.35M 1.18% 12

Other funds holding VTGN

SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Parallax Volatility Advisers
Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

New Leaf Venture Partners's VTGN Position: Q1 2017 in Review

New Leaf Venture Partners sold out of VistaGen Therapeutics (VTGN) in Q1 2017, closing a stake of 11,765 shares — an estimated $1.32M sold.

New Leaf Venture Partners first reported a position in VTGN in Q2 2016 and held it in 3 quarters. The position peaked at $1.49M in Q3 2016. 12 funds tracked by Wall St. Rank hold VTGN as of Q1 2017.

  • New Leaf Venture Partners reported no remaining VistaGen Therapeutics position as of Q1 2017 after selling out during the quarter.
  • New Leaf Venture Partners sold 11,765 VistaGen Therapeutics shares in Q1 2017, an estimated $1.32M.
  • New Leaf Venture Partners first reported a position in VistaGen Therapeutics in Q2 2016 and held it in 3 quarters.
  • New Leaf Venture Partners's VistaGen Therapeutics position peaked at $1.49M in Q3 2016.
  • 12 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2017.

Based on New Leaf Venture Partners's 13F filing for Q1 2017, filed 15 May 2017.